Literature DB >> 15878217

Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain.

Rui Wang1, Mona Boules, Elisa Gollatz, Katrina Williams, William Tiner, Elliott Richelson.   

Abstract

The effects of one or five daily intraperitoneal injections of a neurotensin (NT) receptor agonist NT69L (2 mg/kg, i.p.) on the expression of NT (NTS), dopamine 1 and 2 receptors, tyrosine hydroxylase, and DOPA decarboxylase using immunohistochemical and real-time PCR were investigated in rats. Except for the striatum, acute injection of NT69L did not affect neurotensin receptors as compared to saline control. However, 5 daily injections of NT69L resulted in down-regulation of both NTS-1 protein and mRNA levels in several brain regions with the striatum showing a dramatic decrease in NTS-1 expression (P<0.05). The down-regulation of NTS-1 in the striatum, hypothalamus, and substania nigra (SN) after 5 daily injections was confirmed by autoradiography. Acute injection of NT69L increased NTS-2 mRNA and protein level in prefrontal cortex (PFC). NTS-3 mRNA expression and protein levels were slightly down-regulated in hypothalamus, periaqueductal gray (PAG), and SN, though the difference was not significant. The results indicated a difference in the profile of NT receptors expression in response to NT69L. Tyrosine hydroxylase (TH) and DOPA decarboxylase (DDC) mRNA was significantly down-regulated in striatum but not in SN. Interestingly, Nurr 1, a transcriptional activator of TH, was dramatically up-regulated in striatum, but down-regulated in PFC, suggesting that different modulating mechanisms may participate in NT69L tolerance in different regions. The present results suggest that distinct NT receptors involved in the effects exerted by NT69L may contribute to the interactions of NT69L with both neural networks and cellular proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878217     DOI: 10.1016/j.molbrainres.2005.03.014

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  7 in total

1.  The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Authors:  Kristin E Smith; Mona Boules; Katrina Williams; Abdul H Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2011-06-21       Impact factor: 3.332

2.  Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin.

Authors:  Liuyin Zhang; Hee-Kyoung Lee; Timothy H Pruess; H Steve White; Grzegorz Bulaj
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

3.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

4.  Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Authors:  Siobhan Briody; Mona Boules; Alfredo Oliveros; Irfan Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2009-10-02       Impact factor: 3.332

5.  Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.

Authors:  Adam J Prus; Todd M Hillhouse; Amber L LaCrosse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-23       Impact factor: 5.067

Review 6.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

7.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.